Spots Global Cancer Trial Database for hematologic malignancies
Every month we try and update this database with for hematologic malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) | NCT00231309 | Hematologic Dis... Hematologic Mal... | Granulocyte Col... | - 55 Years | Emory University | |
| Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies | NCT05707325 | Cancer Solid Tumor Hematologic Mal... | engineered red ... | 18 Years - 75 Years | Westlake Therapeutics | |
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy | NCT02139280 | Hematologic Mal... | Cyclophosphamid... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation | NCT01882374 | Hematologic Mal... | TXA127 | 18 Years - | Tarix Pharmaceuticals | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | NCT00795132 | Acute Leukaemia Chronic Disease Leukemia Myelodysplasia Lymphoma | Busulfan Anti-Thymocyte ... Fludarabine Cyclosporine Mycophenolate m... | - 21 Years | University of Utah | |
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate | NCT01844869 | Hematologic Mal... Solid Tumors | omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | NCT00189488 | Graft Versus Ho... Hematologic Mal... | Palifermin Placebo Conditioning Re... Allogeneic stem... Methotrexate | 18 Years - | Swedish Orphan Biovitrum | |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | NCT01810588 | Hematologic Mal... | CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus | 18 Years - | Weill Medical College of Cornell University | |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | NCT04156256 | Hematologic Mal... Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myeloid... | CD123-CD33 cCAR... | - | iCell Gene Therapeutics | |
| Safety of Romiplostim (Nplate®) Following UCBT | NCT02046291 | Hematologic Mal... | Romiplostim | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies | NCT00061620 | Hematologic Mal... | Tezacitabine (F... | 15 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | NCT00270881 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | Cord blood tran... TBI cyclophosphamid... cytarabine | 20 Years - 55 Years | Keio University | |
| Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life | NCT01930981 | Hematologic Mal... Other Diagnoses... | 19 Years - | Fred Hutchinson Cancer Center | ||
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT06378138 | Hematologic Mal... | ICP-248 Orelabrutinib | 18 Years - 80 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Early Palliative Care and Hematological Cancer Patients | NCT03743480 | Hematologic Neo... | early palliativ... | 18 Years - | Arcispedale Santa Maria Nuova-IRCCS | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies | NCT02343679 | Hematologic Mal... | ceritinib | 18 Years - | Duke University | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Effect of Quercetin in Prevention and Treatment of Oral Mucositis | NCT01732393 | Chemotherapy In... | oral quercetin ... Placebo | 15 Years - 40 Years | Mashhad University of Medical Sciences | |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies | NCT01622556 | Hematologic Mal... | Fludarabine Busulfan Thymoglobulin Total Body Irra... Umbilical Cord ... | 18 Years - 70 Years | University of Virginia | |
| Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease | NCT04112810 | Hematologic Mal... | Tildrakizumab | 18 Years - | Medical College of Wisconsin | |
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy | NCT02139280 | Hematologic Mal... | Cyclophosphamid... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| CD34 Selection Using the Automated CliniMACS Prodigy | NCT06047886 | AML ALL Lymphoid Malign... Myelodysplastic... CML Primary Myelofi... | Infusion of CD3... | 4 Weeks - 75 Years | University of Alabama at Birmingham | |
| Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC) | NCT00693927 | Hematologic Mal... | Unmanipulated P... CD8-depleted PB... | - 70 Years | University of Liege | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant | NCT02118311 | Hematologic Mal... | T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra... | 18 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| Phase II Trial of Pentostatin and Targeted Busulfan | NCT00496340 | Hematologic Mal... | Pentostatin Busulfan Rituximab Allogeneic Hema... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | NCT01474681 | Acute Myelocyti... Acute Lymphocyt... Chronic Myeloge... Myelodysplastic... Chronic Lymphoc... Marginal Zone L... Follicular Lymp... Large-cell Lymp... Lymphoblastic L... Burkitt's Lymph... High Grade Lymp... Mantle-cell Lym... Lymphoplasmacyt... | HSC835 | 10 Years - 55 Years | Novartis | |
| Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant | NCT00810602 | Hematologic Mal... Graft vs Host D... | reduced intensi... tacrolimus (sta... mycophenolate (... vorinostat | 18 Years - | University of Michigan Rogel Cancer Center | |
| Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device | NCT02600208 | Hematologic Mal... | CliniMACs | - 23 Years | Medical College of Wisconsin | |
| Matching Patients With Hematologic Malignancy to Adequate Clinical Trials | NCT02758080 | Hematologic Mal... | Matching on the... Matching on the... | 18 Years - | Seoul National University Hospital | |
| Register of Blood Stem Cell Transplantation | NCT04263857 | Hematologic Mal... | 18 Years - | Technical University of Munich | ||
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma | NCT00722488 | Hematologic Mal... Multiple Myelom... Lymphoma Hodgkin Lymphom... | MLN4924 | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | NCT00405743 | Hematologic Mal... AML | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia | NCT01380756 | Cancer Hematologic Mal... Leukemia Myeloid Leukemi... | Arm 1- Dose Esc... Arm 2- Dose Exp... | 18 Years - | Amgen | |
| A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies | NCT02386332 | Hematologic Mal... | transplantation | 18 Years - 55 Years | Instituto de Investigacion Sanitaria La Fe | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | NCT00086125 | Hematologic Mal... Leukemia Myelodysplastic... Myeloid Metapla... Lymphoma | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | NCT00361140 | Myelodysplastic... Myeloproliferat... Leukemia, Lymph... Myeloma Lymphoma | Busulfan Fludarabine | 16 Years - 65 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | NCT02492737 | Acute Myeloid L... Myelodysplastic... Hematologic Mal... | AG881 | 18 Years - | Agios Pharmaceuticals, Inc. | |
| Umbilical Cord Transplantation for the Elderly Population | NCT01484470 | Hematologic Mal... | StemEx | 55 Years - 73 Years | Loyola University | |
| Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation | NCT06028828 | Allogeneic Hema... Allogeneic Stem... Hematologic Mal... | Fludarabine Melphalan Total Body Irra... | 18 Years - 70 Years | University of California, Irvine | |
| Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | NCT00506857 | Hematologic Mal... | Busulfan Fludarabine | - 75 Years | M.D. Anderson Cancer Center | |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | NCT02743351 | Hematologic Mal... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Acute Graft-ver... | ProTmune Control Arm | 18 Years - | Fate Therapeutics | |
| Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction | NCT01912222 | Advanced Solid ... Hematologic Mal... | IXAZOMIB | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | NCT00086125 | Hematologic Mal... Leukemia Myelodysplastic... Myeloid Metapla... Lymphoma | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | NCT00800839 | Hematologic Dis... Leukemia Lymphoma Myeloma | Busulfan Fludarabine Cyclophosphamid... | 6 Months - 75 Years | M.D. Anderson Cancer Center | |
| Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma | NCT01428492 | Multiple Myelom... | GSK2110183 Bortezomib Dexamethasone | 18 Years - | Novartis | |
| A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders | NCT00596999 | Hematologic Mal... | UCB and HPDSC | - 55 Years | Celgene | |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | NCT00809276 | Lymphoma Multiple Myelom... Leukemia Myelodysplastic... | Busulfan, Fluda... | - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Consolidation Therapy in Patients With Hematologic Malignancies | NCT02709993 | Cancer Hematologic Mal... | TAPA-pulsed DC ... | 18 Years - | Kiromic BioPharma Inc. | |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | NCT05322850 | Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Acute Undiffere... Chronic Myeloid... Chronic Myeloid... Chronic Myeloid... | Orca-Q | - 50 Years | University of Florida | |
| A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | NCT00499239 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | GS-9219 | 18 Years - | Gilead Sciences | |
| Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies | NCT04298892 | Haematologic Di... Haematological ... | clinical data a... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation | NCT02786628 | Malignant Solid... Hematologic Mal... Planned Hematop... | Physical perfor... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma | NCT01445587 | Cancer | Part 1; Cohort ... Part 1; Cohort ... Part 2; Stage 1 Part 2, Stage 2 | 18 Years - | GlaxoSmithKline | |
| Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen | NCT01328496 | Hematologic Mal... Disorder Relate... Hematopoietic M... | Preparative Reg... | - 21 Years | St. Jude Children's Research Hospital | |
| Clinical Cohort of Lymphoma Patients in Malawi | NCT02835911 | Lymphoma Hematologic Mal... | 0 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | ||
| A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care | NCT01725022 | Hematologic Mal... | Home Care | 18 Years - 80 Years | Duke University | |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT06378138 | Hematologic Mal... | ICP-248 Orelabrutinib | 18 Years - 80 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies | NCT02473757 | Lyphoma, B-Cell Leukemia, B-cel... Multiple Myelom... Hematologic Mal... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States | NCT00997386 | Hematologic Neo... Multiple Myelom... Anemia, Aplasti... Hemoglobinuria,... Myelofibrosis | busulfan, and m... | 18 Years - 75 Years | University of Arizona | |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies | NCT02145403 | Hematologic Mal... Relapse Graft-Versus-Ho... | Carfilzomib Tacrolimus | 18 Years - 70 Years | University of Michigan Rogel Cancer Center | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative | NCT00429143 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate M... Hematopoietic S... | 18 Years - | Thomas Jefferson University | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | NCT00469729 | Hematologic Mal... Acute Myeloid L... Lymphoid Leukem... Chronic Myeloid... Hodgkin's Disea... Non-Hodgkin's L... Myelodysplastic... | StemEx® | 12 Years - 55 Years | Gamida Cell -Teva Joint Venture Ltd. | |
| Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States | NCT00997386 | Hematologic Neo... Multiple Myelom... Anemia, Aplasti... Hemoglobinuria,... Myelofibrosis | busulfan, and m... | 18 Years - 75 Years | University of Arizona | |
| Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) | NCT01344707 | Advanced Hemato... | 4SC-202 | 18 Years - | 4SC AG | |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | NCT00270881 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | Cord blood tran... TBI cyclophosphamid... cytarabine | 20 Years - 55 Years | Keio University | |
| An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies | NCT05433090 | Hematologic Mal... | Inpatient serio... | 60 Years - | University of Rochester | |
| Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation | NCT01316549 | Hematologic Mal... Nonmalignant Di... Immunodeficienc... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Fludarabine | - 17 Years | University of California, San Francisco | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | NCT03082209 | Advanced Solid ... Cancer Hematologic Mal... | ABBV-621 Venetoclax Bevacizumab FOLFIRI | 18 Years - | AbbVie | |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | NCT04728893 | Hematologic Mal... Waldenstroms Ma... Non-Hodgkins Ly... Chronic Lymphoc... | Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | NCT00890500 | Hematologic Mal... Allogeneic Stem... | Fludarabine Melphalan Antithymocyte G... Sirolimus Tacrolimus | 18 Years - 65 Years | Fate Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
